Brian Gormley of The Wall Street Journal has featured Ochre Bio and their novel approach to tackling chronic liver disease (a top ten cause of death globally).
“We’re starting with a focus on improving outcomes for transplant patients, and are making exciting progress scientifically here in Oxford. With great investors onboard, a wonderful team coming together, and an international network of transplant / clinical partners – we are well on our way to developing life-saving medicines for one of the toughest healthcare challenges of our time” said Ochre Bio.